GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com

Posted by Jessica Moore on Mar 1st, 2025

StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note published on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

GlycoMimetics Price Performance

Shares of GlycoMimetics stock opened at $0.27 on Wednesday. GlycoMimetics has a fifty-two week low of $0.14 and a fifty-two week high of $3.18. The firm has a fifty day moving average price of $0.27 and a two-hundred day moving average price of $0.25.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. As a group, analysts expect that GlycoMimetics will post -0.08 EPS for the current fiscal year.

Institutional Trading of GlycoMimetics

A number of hedge funds have recently bought and sold shares of the stock. Caxton Corp bought a new stake in GlycoMimetics in the 4th quarter valued at $51,000. ADAR1 Capital Management LLC boosted its holdings in GlycoMimetics by 626.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 286,127 shares during the period. Jefferies Financial Group Inc. acquired a new position in shares of GlycoMimetics in the 4th quarter valued at $106,000. Wellington Management Group LLP acquired a new position in shares of GlycoMimetics in the 4th quarter valued at $352,000. Finally, VR Adviser LLC acquired a new position in shares of GlycoMimetics in the 4th quarter valued at $747,000. 75.19% of the stock is owned by institutional investors.

GlycoMimetics Company Profile

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.